KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Liabilities and Shareholders Equity: 2013-2025

Historic Liabilities and Shareholders Equity for Xenon Pharmaceuticals (XENE) over the last 11 years, with Sep 2025 value amounting to $607.8 million.

  • Xenon Pharmaceuticals' Liabilities and Shareholders Equity fell 27.28% to $607.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.8 billion, marking a year-over-year decrease of 21.65%. This contributed to the annual value of $798.1 million for FY2024, which is 17.27% down from last year.
  • Xenon Pharmaceuticals' Liabilities and Shareholders Equity amounted to $607.8 million in Q3 2025, which was down 9.85% from $674.3 million recorded in Q2 2025.
  • Xenon Pharmaceuticals' Liabilities and Shareholders Equity's 5-year high stood at $964.8 million during Q4 2023, with a 5-year trough of $264.4 million in Q3 2021.
  • Over the past 3 years, Xenon Pharmaceuticals' median Liabilities and Shareholders Equity value was $743.3 million (recorded in 2025), while the average stood at $773.0 million.
  • Its Liabilities and Shareholders Equity has fluctuated over the past 5 years, first surged by 202.35% in 2021, then dropped by 27.28% in 2025.
  • Xenon Pharmaceuticals' Liabilities and Shareholders Equity (Quarterly) stood at $572.0 million in 2021, then skyrocketed by 31.84% to $754.1 million in 2022, then grew by 27.93% to $964.8 million in 2023, then declined by 17.27% to $798.1 million in 2024, then declined by 27.28% to $607.8 million in 2025.
  • Its last three reported values are $607.8 million in Q3 2025, $674.3 million for Q2 2025, and $743.3 million during Q1 2025.